CarpeDiab in its final stages

30 April 2019

The CarpeDiab project consortium met on 20 March at IDF Europe’s offices in Brussels with the aim of following up the group’s app development.

CarpeDiab objective is to be an advanced service for type 2 diabetes management. The project, which has received funding from the EU’s Horizon 2020 initiative, is expected to have an impact on the behaviour of people and their healthcare professionals to take full advantage of the possibilities offered by technology.

The objective of the meeting was to follow up on the development of IT solutions for the CarpeDiab app. The outcomes will be used to finalize the development of these solutions.

Members of a consortium participated in the meeting, including IDFE professional officer Ernest Karurangan, Claudio Eccher from Fondazione Bruno Kessler and Marco d’Angelantonio from Health Insight Solutions.

IDF Europe is part of the consortium and contributes to medical knowledge and patient empowerment. The consortium brings expertise from six European countries: Italy, the Netherlands, Türkiye, Spain, Belgium and Germany.

Learn more about IDF Europe’s role in the CarpeDiab project.